Vincerx Pharma Terminates Sales Agreement with Leerink Partners LLC and Holds Special Meeting of Stockholders

On January 10, 2025, Vincerx Pharma, Inc. announced the termination of its Sales Agreement with Leerink Partners LLC, which was initially dated March 29, 2024. This agreement allowed the company to offer and sell shares of its common stock with an aggregate offering price of up to $50,000,000 through “at-the-market” offerings as defined in Rule […]

Leave a Reply

Your email address will not be published.

Previous post Ross Stores, Inc. (NASDAQ:ROST) Shares Acquired by Hennion & Walsh Asset Management Inc.
Next post Elevai Labs (NASDAQ: ELAB) Resolves Nasdaq Compliance Issues and Announces Subsidiary Name Changes